Cardiology and cardiovascular disease Archives

COVID-19 therapy and vaccination: a clinical narrative review

Siddharth Chinta, Miguel Rodriguez-Guerra, Mohammed Shaban, Neelanjana Pandey, Maria Jaquez-Duran, Timothy J Vittorio

Article Type

Review

Published

07 Feb 2023

This review discusses how the SARS-CoV-2 pandemic has progressed and surged, and summarizes the safety and efficacy of the most used therapies and vaccines in the light of recent evidence.

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction

Oscar Eduardo Ospina González, Diana Catalina Llanos Mejía, Edgardo Kaplinsky, Alejandro Barbagelata, Sergio Perrone

Article Type

Review

Published

04 Jan 2023

This article reviews an updated therapeutic algorithm for heart failure with reduced ejection fraction (HFrEF) with a special focus on the therapeutic value of adding an mineralocorticoid receptor antagonist, changing an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for an angiotensin
II receptor-neprilysin inhibitor and incorporating an sodium–glucose cotransporter 2 inhibitor in patients with HFrEF.

Emerging concepts in heart failure management and treatment: focus on vericiguat

Edgardo Kaplinsky, Sergio Perrone, Alejandro Barbagelata

Article Type

Review

Published

04 Jan 2023

This review provides comprehensive information about vericiguat in terms of its differential mechanism of action and clinical data particularly focused on the VICTORIA trial.

Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction

Andrea Beatriz De Lorenzi, Edgardo Kaplinsky, Marx Rivera Zambrano, Laia Tomás Chaume, Joan Monell Rosas

Article Type

Review

Published

04 Jan 2023

This article provides an overview of the main pathophysiological characteristics of heart failure with preserved ejection fraction (HFpEF), the considered diverse biological effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in this context and the supporting clinical evidence of SGLT2i in patients with HFpEF with a focus on the EMPEROR-Preserved and DELIVER trials.

Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy

María Victoria Báez Cabanillas, Roberto Colque, Miguel Ángel Tibaldi, Edgardo Kaplinsky, Sergio Perrone, Alejandro Barbagelata

Article Type

Review

Published

04 Jan 2023

The author present a narrative review that comprehensively addresses the pathophysiology, clinical manifestations, and therapeutic management of tachycardia-induced cardiomyopathy.